The Rise of Neurotechnology in India: From Research Labs to Commercial Markets

Executive summary

For decades, neurotechnology in India was largely associated with neuroscience laboratories, medical institutions and academic research. Brain signals were studied, neurological disorders were investigated, and experimental technologies were developed primarily within controlled research environments.

That landscape is beginning to change. India is seeing the emergence of companies working on brain-computer interfaces, neuromodulation, neurodiagnostics, brain imaging, biosignal platforms and cognitive technologies. Advances in artificial intelligence, sensors and medical devices are making it increasingly possible to translate neuroscience research into practical products.

The transition is significant because India is no longer looking only at how neurotechnology can advance scientific research. The larger question is whether India can convert its neuroscience, AI and engineering capabilities into commercially scalable neurotechnology. The early signals suggest that opportunity is beginning to take shape.

What is neurotechnology and why is it gaining attention?

Neurotechnology broadly refers to technologies designed to measure, interpret or influence activity in the brain and nervous system. The category includes:

• Brain-computer interfaces
• Electroencephalography (EEG) systems
• Neural sensing and biosignal platforms
• Neurostimulation and neuromodulation
• AI-powered neurological diagnostics
• Brain imaging and mapping
• Assistive communication technologies
• Cognitive and neuro-wellness devices

Brain-computer interfaces have attracted particularly strong global attention. BCIs capture signals produced by the brain and translate them into commands that can interact with computers, communication systems, prosthetics or other devices. India's opportunity, however, may develop differently from the implant-heavy strategies receiving the most global attention.

Analysis of India's BCI landscape points to potential in affordable and non-invasive neurotechnology, assistive communication, neurorehabilitation and human-machine interaction. This could give India an opportunity to compete not only on technological sophistication but also on accessibility, affordability and scale.

India's neurotechnology ecosystem is moving beyond research

India already has an established base of neuroscience researchers, engineering institutions, medical centres and technology talent. What is changing is the commercial layer around that research.

An emerging group of Indian neurotechnology startups is attempting to transform neuroscience and biosignal research into products that can be used by hospitals, clinicians, researchers and consumers. The ecosystem spans consumer neurotechnology and clinical neuromodulation through to brain imaging, biosignal infrastructure and computational neuroscience.

A sustainable neurotechnology ecosystem requires capabilities across an entire value chain:

Consumer neurotechnology is creating a new market

Devices that once required specialist laboratory environments are gradually becoming smaller, wearable and easier to use. One emerging example is Temple, founded by Zomato founder Deepinder Goyal. According to Neurofounders, the company raised US$54 million in seed funding and is developing a temple-worn patch intended to measure cerebral blood flow in real time. Initial applications include indicators related to focus, fatigue, cognitive strain and performance.

Mave Health is developing Arc, a wearable headset using transcranial direct current stimulation (tDCS). Neurofounders reports that the company raised US$2.1 million in seed funding to support its India and US launches and expand manufacturing.

These developments point to a broader shift. Neurotechnology is beginning to move from specialised laboratory equipment toward products designed for regular, real-world use, opening commercial categories around cognitive performance, wellness, productivity and personalised neurological insights.

Clinical neurotechnology could become an even larger opportunity

While consumer applications may increase visibility, healthcare could become one of the most important markets for Indian neurotechnology. India faces a significant burden from neurological and mental-health conditions, while specialist healthcare capacity remains unevenly distributed. Portable and non-invasive neurotechnology could help address some of that gap.

Marbles Health has developed EASE, a portable transcranial direct current stimulation system. Neurofounders reports that the device has received CDSCO approval in India and is positioned for applications including depression, anxiety and addiction.

This represents an important commercial pathway for Indian neurotech companies. Instead of immediately competing in complex and capital-intensive implanted neural interfaces, Indian companies can build solutions that are non-invasive, portable, clinically relevant, more affordable and easier to deploy.

Brain-computer interfaces could become a strategic opportunity

Global investment in BCIs is increasing as researchers and companies explore more direct communication between the human brain and machines. The Economic Times reported, citing Tracxn data, that India ranked third globally by number of BCI startups, with approximately a dozen companies, behind the United States and China.

India's competitive position does not necessarily depend on replicating implant-heavy strategies. Its opportunity may lie in accessible, non-invasive and commercially deployable BCI technologies across:

• Assistive communication: helping people with severe motor disabilities interact with computers and communication devices.
• Neurorehabilitation: supporting recovery of motor or cognitive functions following neurological injuries.
• Clinical monitoring: combining brain signals with AI to identify neurological patterns and abnormalities.
• Human-machine interaction: developing new ways for people to interact with software, machines and connected devices.
• Cognitive applications: measuring attention, fatigue, cognitive load and other neurological signals.

AI is becoming the intelligence layer of neurotechnology

Brain data is complex. EEG recordings, neural signals and brain imaging can generate enormous volumes of information that are difficult to interpret manually. AI can help convert these signals into useful clinical or commercial insights.

BrainSightAI is developing AI-driven brain mapping and neuroimaging technologies. Neurofounders reports that the company raised US$5 million in pre-Series A funding in January 2025 and has worked on applications involving brain tumours, dementia, stroke, Parkinson's disease and psychiatric disorders.

NeuroDX has introduced MANAS-1, described as a 400-million-parameter brain foundation model trained on 60,000 hours of EEG recordings from more than 25,000 patients. The model is intended to support neurological screening, disease detection and clinical decision-making.

Building the infrastructure behind Indian neurotech

Every emerging technology sector eventually needs infrastructure. Neurotechnology is no different. Companies need reliable sensors, biosignal acquisition systems, datasets, development platforms, research tools and software infrastructure before they can build scalable applications.

Bengaluru-based Anthriq, previously known as Nexstem, illustrates this layer of the ecosystem. The company has expanded from its original non-invasive BCI positioning toward a broader biosignal platform covering signals such as EEG, ECG, EMG and EOG. Under its previous identity, the company raised US$3.5 million in 2024 to expand its BCI and biosignal ecosystem, according to Neurofounders.

Companies building underlying infrastructure could become particularly important. If Indian researchers and startups can access affordable domestic hardware, datasets and development tools, the cost and time required to build new neurotechnology products could fall significantly.

Capital is beginning to follow the opportunity

In August 2026, SPEC Finance announced ADI Neuroscience, a ₹10,000 crore neurotechnology-focused fund intended to accelerate research and development in India over the next five years. According to the Economic Times, the initiative plans to invest in Indian neurotech startups, scientific teams and laboratories while connecting researchers, businesses and global capital.

The scale of this commitment is significant because neurotechnology requires a different investment mindset from conventional software. A typical company may have to move through research, prototype, validation, clinical evidence, regulatory approval, manufacturing, market access and adoption. Each stage requires time and capital, making patient capital particularly important.

The bigger challenge is commercialisation

Developing sophisticated technology is only one part of building a neurotechnology company. The larger challenge is moving from a successful research prototype to a product that customers will actually adopt.

• Does the technology solve a valuable problem? Scientific novelty does not automatically translate into market demand.
• Can it work reliably outside a laboratory? Real-world environments introduce variables controlled research settings may not capture.
• Who is the customer and who pays? The user may be a patient, but the buyer could be a hospital, rehabilitation centre, insurer, employer or healthcare provider.
• What regulatory pathway applies? A wellness product and a medical device may require very different levels of evidence and approval.
• Can manufacturing scale? Hardware and software businesses need reliable manufacturing, quality assurance and supply chains.
• Can clinicians and institutions integrate it into existing workflows? Healthcare technologies need physician confidence, hospital acceptance and evidence of practical value.

For Indian neurotech companies, this commercialisation gap may ultimately prove more difficult than the original scientific challenge.

Regulation will need to evolve alongside innovation

Neurotechnology introduces regulatory questions that extend beyond conventional medical devices or digital platforms. Brain and neural data can be deeply sensitive. As the technology becomes more powerful, companies and policymakers will need to address neural-data ownership, patient and user consent, cognitive privacy, medical versus wellness claims, cybersecurity of connected neurodevices, AI interpretation of neurological signals, long-term safety of stimulation technologies, use in workplaces and education, and human autonomy.

Standards, regulatory frameworks and markets remain at an early stage of development. India therefore has an opportunity to shape regulation while the market is still emerging by allowing responsible experimentation while establishing strong standards around safety, privacy, evidence and informed consent.

India's advantage could be affordable neurotechnology at scale

India does not necessarily need to win the global neurotechnology race by creating the world's most complex brain implant. There may be a more strategically attractive opportunity: affordable neural sensors, non-invasive interfaces, AI interpretation, portable devices and large-scale healthcare deployment.

That model could address significant unmet needs within India while creating technologies relevant to other emerging markets. Countries across Southeast Asia, Africa and the Middle East face similar challenges: rising healthcare demand, limited specialist capacity and pressure to make advanced medical technologies more affordable. Indian neurotechnology companies that solve these problems domestically could have a natural pathway into international markets.

From building technology to building a neurotech market

The next stage of India's neurotechnology journey will require stronger connections between research institutions, healthcare providers, investors, regulators, manufacturers and commercial partners.

1. Research must connect more directly with commercialisation. Universities and research institutions need stronger pathways for converting neuroscience intellectual property into startups, licensing opportunities and industry partnerships.
2. Investment must extend beyond product development. Funding cannot stop at the prototype. Companies need capital for clinical validation, regulatory approval, manufacturing, market testing and healthcare integration.
3. Market strategy must begin earlier. Startups should answer who the buyer is, what evidence they require, which regulatory pathway applies, how the technology enters clinical workflows, who pays and which partners are needed while the technology is still being developed.

GreyRadius perspective: the opportunity is bigger than the BCI race

The global neurotechnology conversation is often dominated by futuristic images of implanted chips and direct brain-machine communication. India's opportunity may be much broader. The emerging ecosystem is developing across neural sensing, BCIs, neuromodulation, AI diagnostics, brain imaging, biosignal infrastructure and consumer neurotechnology.

India already has strong technology talent, medical institutions, a large healthcare market and a growing deep-tech ecosystem. What it needs next is a stronger commercialisation engine connecting science with regulation, capital, manufacturing and market access.

From research labs to commercial markets

Indian neurotechnology remains an early-stage market, but the direction is becoming clearer. Research capabilities are being converted into startups. AI is improving the interpretation of neurological data. Consumer and clinical products are reaching the market. Dedicated investment is emerging. Companies are beginning to build infrastructure around biosignals and neural data.

The next five years could determine whether India remains primarily a contributor to global neuroscience research or becomes a meaningful commercial neurotechnology ecosystem. Success will not be measured simply by how many BCI startups India creates. It will be measured by how effectively the country converts scientific capability into validated products, scalable companies and globally competitive intellectual property.

Frequently asked questions

What is neurotechnology? +

Neurotechnology refers to technologies that measure, interpret or influence the brain and nervous system. It includes brain-computer interfaces, EEG systems, neural sensors, neurostimulation, brain imaging, AI-powered neurological diagnostics and cognitive technologies.

How is the neurotechnology market developing in India? +

India's neurotechnology ecosystem is moving from academic research toward commercial applications. Startups are emerging across BCIs, neuromodulation, neurodiagnostics, brain imaging, biosignal platforms and consumer neurotechnology.

What are the biggest neurotechnology opportunities in India? +

Promising areas include non-invasive BCIs, neurological diagnostics, rehabilitation, assistive communication, neuromodulation, AI-powered brain imaging, biosignal analysis and affordable neurological devices.

Why could India become important in global neurotechnology? +

India combines AI and engineering talent, neuroscience research, medical institutions, a large healthcare market and relatively cost-efficient technology development. These capabilities could support affordable neurotechnology for India and other emerging markets.

What challenges do neurotechnology startups face in India? +

Major challenges include clinical validation, regulatory clarity, patient capital, manufacturing scale, neural-data privacy, healthcare adoption and sustainable business and reimbursement models.